Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor‑positive/human epidermal growth factor receptor 2‑negative advanced breast cancer: an age‑specific subgroup analysis of MONARCH 2 and 3 trials

Author(s): Matthew P. Goetz et al.

Published: 1 April 2021

Copyright: The Author(s) 2021

By accessing this content you are agreeing to the following terms and conditions, and certifying that the content provided is for your personal use only.

  • The modification, adaptation, manipulation, transformation, translation or creation of derivative works based on the materials is prohibited
  • The user may not remove, obscure or modify any copyright or other notices or disclaimers included in the materials
  • The user may not transmit in any format the materials to other persons
  • Printing copies for distribution for any reason is strictly prohibited
  • The user will take all reasonable security measures necessary to prevent unauthorised duplication or unauthorised distribution of the materials
  • You accept Springer Healthcare’s Privacy Policy
Voucher code (required)
Your Name (required)
Your Email (required)
This is no longer available.